MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018 | Danskeaktier.com

Fondsbørsmeddelelse

Læs den fulde meddelelse hos Globenewswire:
Gå til Globenewswire

Hoersholm, Denmark, June 1, 2018 - Medical Prognosis Institute A/S ("MPI") hereby announces that clinical data on PARP inhibitor 2X-121 and DRP response prediction validation is to be presented on the world's largest cancer congress ASCO 2018 on June 1st 2018.

Vi indsamler aktuelle aktiekurser og fondsbørsmeddelelser for alle danske aktier.
Se også vores aktietips og aktieanbefalinger eller deltag i vores aktiekursus

Mest populære aktie: Novo Nordisk Aktie